Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al. · International Journal of Cancer · 2014 · 29K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Kisten ras mutations in patients with colorectal cancer: the “RASCAL II” study.

David Cunningham, J. Oates, Joanne Young et al. · IRIS UNIMORE (University of Modena and Reggio Emilia) · 2001 · 890 citations · Full text

Medicine, Genetics, Oncology +12

Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

Silvia Benvenuti, Andrea Sartore‐Bianchi, Federica Di Nicolantonio et al. · Cancer Research · 2007 · 830 citations · Full text

Medicine, Cancer Biology, Oncology +16

<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

Susan D. Richman, Philip Chambers, Faye Elliott et al. · Journal of Clinical Oncology · 2009 · 569 citations

Medicine, Molecular Genetics, Oncology +17

Prevalence and Heterogeneity of <i>KRAS, BRAF</i>, and <i>PIK3CA</i> Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

Stephan Baldus, Karl-L. Schaefer, Rainer Engers et al. · Clinical Cancer Research · 2010 · 433 citations

Medicine, Molecular Genetics, Oncology +17